Novartis
NEWS
Joseph Jimenez retires at the end of the month after eight years in the top job at Novartis.
Entresto, introduced in 2015, got off to a slow start but brought in $507 million in revenue last year.
Narasimhan takes over the role of CEO in February as current CEO Joe Jimenez retires.
Life sciences professionals don’t have to look far for opportunity in Genetown.
Novartis has found its new chief of oncology.
2017 was the second-best year for FDA approvals since 1996.
A look at the lucky drugs that have been hailed a breakthrough by the FDA.
A Novartis drug approved as a second-line treatment for a blood disorder snagged the FDA’s Breakthrough Therapy Designation as a first-line defense.
The company said the Breakthrough Therapy Designation is based on positive results from the Phase III MONALEESA-7 trial.
JOBS
IN THE PRESS